PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CABA vs. OLMA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CABA and OLMA is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

CABA vs. OLMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cabaletta Bio, Inc. (CABA) and Olema Pharmaceuticals, Inc. (OLMA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-63.56%
-58.40%
CABA
OLMA

Key characteristics

Sharpe Ratio

CABA:

-0.85

OLMA:

-0.83

Sortino Ratio

CABA:

-2.27

OLMA:

-1.31

Omega Ratio

CABA:

0.74

OLMA:

0.85

Calmar Ratio

CABA:

-0.98

OLMA:

-0.71

Martin Ratio

CABA:

-1.28

OLMA:

-1.76

Ulcer Index

CABA:

71.15%

OLMA:

36.94%

Daily Std Dev

CABA:

106.81%

OLMA:

78.73%

Max Drawdown

CABA:

-96.63%

OLMA:

-96.26%

Current Drawdown

CABA:

-91.53%

OLMA:

-90.53%

Fundamentals

Market Cap

CABA:

$105.09M

OLMA:

$383.10M

EPS

CABA:

-$2.16

OLMA:

-$2.28

Total Revenue (TTM)

CABA:

$0.00

OLMA:

$0.00

Gross Profit (TTM)

CABA:

-$819.00K

OLMA:

-$182.00K

EBITDA (TTM)

CABA:

-$90.11M

OLMA:

-$105.21M

Returns By Period

In the year-to-date period, CABA achieves a -5.29% return, which is significantly higher than OLMA's -11.49% return.


CABA

YTD

-5.29%

1M

-21.53%

6M

-63.56%

1Y

-90.53%

5Y*

-33.15%

10Y*

N/A

OLMA

YTD

-11.49%

1M

-8.83%

6M

-58.39%

1Y

-64.02%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CABA vs. OLMA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CABA
The Risk-Adjusted Performance Rank of CABA is 44
Overall Rank
The Sharpe Ratio Rank of CABA is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of CABA is 11
Sortino Ratio Rank
The Omega Ratio Rank of CABA is 22
Omega Ratio Rank
The Calmar Ratio Rank of CABA is 11
Calmar Ratio Rank
The Martin Ratio Rank of CABA is 1111
Martin Ratio Rank

OLMA
The Risk-Adjusted Performance Rank of OLMA is 66
Overall Rank
The Sharpe Ratio Rank of OLMA is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of OLMA is 66
Sortino Ratio Rank
The Omega Ratio Rank of OLMA is 88
Omega Ratio Rank
The Calmar Ratio Rank of OLMA is 77
Calmar Ratio Rank
The Martin Ratio Rank of OLMA is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CABA vs. OLMA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Cabaletta Bio, Inc. (CABA) and Olema Pharmaceuticals, Inc. (OLMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CABA, currently valued at -0.85, compared to the broader market-2.000.002.00-0.85-0.83
The chart of Sortino ratio for CABA, currently valued at -2.27, compared to the broader market-4.00-2.000.002.004.006.00-2.27-1.31
The chart of Omega ratio for CABA, currently valued at 0.74, compared to the broader market0.501.001.502.000.740.85
The chart of Calmar ratio for CABA, currently valued at -0.98, compared to the broader market0.002.004.006.00-0.98-0.71
The chart of Martin ratio for CABA, currently valued at -1.28, compared to the broader market0.0010.0020.0030.00-1.28-1.76
CABA
OLMA

The current CABA Sharpe Ratio is -0.85, which is comparable to the OLMA Sharpe Ratio of -0.83. The chart below compares the historical Sharpe Ratios of CABA and OLMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40SeptemberOctoberNovemberDecember2025February
-0.85
-0.83
CABA
OLMA

Dividends

CABA vs. OLMA - Dividend Comparison

Neither CABA nor OLMA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CABA vs. OLMA - Drawdown Comparison

The maximum CABA drawdown since its inception was -96.63%, roughly equal to the maximum OLMA drawdown of -96.26%. Use the drawdown chart below to compare losses from any high point for CABA and OLMA. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%SeptemberOctoberNovemberDecember2025February
-91.53%
-90.53%
CABA
OLMA

Volatility

CABA vs. OLMA - Volatility Comparison

Cabaletta Bio, Inc. (CABA) has a higher volatility of 25.29% compared to Olema Pharmaceuticals, Inc. (OLMA) at 20.75%. This indicates that CABA's price experiences larger fluctuations and is considered to be riskier than OLMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
25.29%
20.75%
CABA
OLMA

Financials

CABA vs. OLMA - Financials Comparison

This section allows you to compare key financial metrics between Cabaletta Bio, Inc. and Olema Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab